[Bio Peptide Co](/)

From the body [GLP-1](/glp-1#origin-glp1) [GHRH](/ghrh#origin-ghrh) [The thymus](/signal-families#origin-thymus)

[Overview](/)

Into adaptations [Semaglutide](/glp-1#adaptation-glp1) [Sermorelin & tesamorelin](/ghrh#adaptation-ghrh) [PT-141](/signal-families#adaptation-alpha-msh)

[The seven families](/)

A fragment and a copper companion

# A fragment and a copper companion

These two stories don’t begin with a hormone copied into a medicine. One starts with a protein fragment, the other with a peptide that binds copper. The details help us see where the resemblance ends.

## Copper in the name

![A copper offcut catches warm light on a stone work surface.](/co-messages-84b5455dae08/copper-surface.webp)

Copper is the namesake here; metal is not a picture of a treatment.

The Cu in GHK-Cu means copper. The metal in the photo is its namesake, rather than evidence about skin. For that, we need to look at what researchers actually tested.

## A stomach-protein sequence and BPC-157

### Origin · A stomach-protein fragment

BPC-157 is described as coming from part of a protein in human gastric juice, the fluid in the stomach. That’s the origin story. It doesn’t make BPC-157 a naturally circulating messenger.

This is a different relationship from the one between GLP-1 and semaglutide. “Related to something in the body” can mean quite different things.

### Adaptation · Synthetic BPC-157

BPC-157 is a synthetic fragment. Most repair findings come from animals. A [review of the evidence](https://pubmed.ncbi.nlm.nih.gov/40789979/) found very little human research and a lack of large, rigorous trials.

An animal result can be interesting without answering what happens to a person with an injury. The missing human evidence is a real gap.

**What the relationship cannot establish.**  BPC-157 isn’t FDA-approved. Long-term human safety is unknown, and the stomach connection doesn’t establish a safe healing treatment.

## GHK and its copper companion

### Origin · GHK

GHK is a peptide made of three protein building blocks. It’s found naturally in human fluids and binds copper to form GHK-Cu. The [GHK review](https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/) explains that connection.

### Adaptation · Cosmetic and research contexts

You may meet the name copper tripeptide-1 in skincare. In [a study of cells grown in a lab](https://pubmed.ncbi.nlm.nih.gov/3169264/), GHK-Cu increased collagen production. Those were connective-tissue cells, rather than people using a cream or an injection.

Cosmetic use is a separate context. [FDA’s cosmetic rules](https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated) differ from drug approval; a familiar skincare ingredient isn’t automatically an approved medicine.

**What the relationship cannot establish.**  GHK-Cu has no FDA-approved drug use. FDA flags possible immune reactions and limited human safety information for injections. Skin-cream findings don’t answer that safety question.

## A withdrawn request isn’t a green light

On the [FDA page current as of April 22, 2026](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks), BPC-157 and injectable GHK-Cu are listed as “nominated but withdrawn”. The groups that requested review took those requests back. FDA still lists safety concerns.

That isn’t clearance, Category 1 placement or approval for compounding. FDA gives no withdrawal date for either entry. The date above belongs to the page, not to a decision about either substance.

For an injury or skin concern, a licensed U.S. clinician can assess what fits, including approved treatment where appropriate. The origin story can help explain a name. It can’t do that assessment.

We follow the body’s messages here as a guide; Bio Peptide Co is not a clinic, pharmacy or seller.

[References](/references) [About the guide](/about) [Contact](/contact) [Read in Markdown](/index.md)

© 2026 Bio Peptide Co